Neurol. praxi. 2019;20(3):204-207 | DOI: 10.36290/neu.2019.113
Ocrelizumab, clinical aktivity and progression – long-term data
- Neurologická klinika LF a FN Hradec Králové
Multiple sclerosis is a chronic inflammatory demyelinating disease which affect central nervous system. Treatment options in multiple
sclerosis have expanded considerably in the recent years. This article deals with new data about clinical activity, influencing
of disease progresion among patients treated with ocrelizumab.
Keywords: multiple sclerosis, ocrelizumab, CDP, PIRA, RAW
Published: June 12, 2019 Show citation
References
- Hauser SL, Bar Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigator. Ocrelizumab versus Interferon Beta 1a in Relapsing Multiple Sclerosis. N Engl J Med 2017; 376: 221-220.
Go to original source... - Hauser SL, Brochet B, Montalban X, Naismith RT, Wolinsky JS, Manfrini M, Garas M, Villoslada P, Model F, Hubeaux S, Kappos L Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Poster presented at: 34st ECTRIMS Annual Congress; October 10-12, 2018; Berlin, Germany. Poster Session; P590. Go to original source...
- Hauser SL, Kappos L, Montalban X, Hughes R, Koendgen H, McNamara J, Pradhan A, Wormser D, Wolinsky JS, Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Poster presented at: 34st ECTRIMS Annual Congress; October 10-12, 2018; Berlin, Germany. Poster Session; P1229. Go to original source...
- Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Manfrini M, Belachev S, Hauser SL. Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies. Poster presented at: 34st ECTRIMS Annual Congress; October 10-12, 2018; Berlin, Germany. Poster Session; P547. Go to original source...
- Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, Hopfner KP, Uma?a P, Niederfellner G. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013 Jan-Feb; 5(1): 22-33. Go to original source...
Go to PubMed... - Krejsek J. Novinky v patogenezi roztroušené sklerózy. Co je skryto za disabilitou pacientů s RS. Remedia 2014: S2-4.
- Krejsek J. Biologická terapie ocrelizumabem (antiCD20) je překvapivě klinicky účinná u nemocných s roztroušenou sklerózou mozkomíšní. Neurol. praxi 2017; 18(6): 403-407. Go to original source...
- Lycke J. Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord. 2015; 8(6): 274-293. Go to original source... Go to PubMed...
- Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017; 376: 221-234. Go to original source...
- Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, Deol-Bhullar G, Garren H, Chin P, Belachew S, Kappos L. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Ann Neurol. 2018 Aug 29. doi: 10.1002/ana.25313. Go to original source...